Navigation Links
Vitamin D increases breast cancer patient survival
Date:3/6/2014

Breast cancer patients with high levels of vitamin D in their blood are twice as likely to survive the disease as women with low levels of this nutrient, report University of California, San Diego School of Medicine researchers in the March issue of Anticancer Research.

In previous studies, Cedric F. Garland, DrPH, professor in the Department of Family and Preventive Medicine, showed that low vitamin D levels were linked to a high risk of premenopausal breast cancer. That finding, he said, prompted him to question the relationship between 25-hydroxyvitamin D a metabolite produced by the body from the ingestion of vitamin D and breast cancer survival rates.

Garland and colleagues performed a statistical analysis of five studies of 25-hydroxyvitamin D obtained at the time of patient diagnosis and their follow-up for an average of nine years. Combined, the studies included 4,443 breast cancer patients.

"Vitamin D metabolites increase communication between cells by switching on a protein that blocks aggressive cell division," said Garland. "As long as vitamin D receptors are present tumor growth is prevented and kept from expanding its blood supply. Vitamin D receptors are not lost until a tumor is very advanced. This is the reason for better survival in patients whose vitamin D blood levels are high."

Women in the high serum group had an average level of 30 nanograms per milliliter (ng/ml) of 25-hydroxyvitamin D in their blood. The low group averaged 17 ng/ml. The average level in patients with breast cancer in the United States is 17 ng/ml.

"The study has implications for including vitamin D as an adjuvant to conventional breast cancer therapy," said co-author Heather Hofflich, DO, UC San Diego associate professor in the Department of Medicine.

Garland recommended randomized controlled clinical trials to confirm the findings but suggested physicians consider adding vitamin D into a breast cancer patient's standard care now and then closely monitor the patient.

"There is no compelling reason to wait for further studies to incorporate vitamin D supplements into standard care regimens since a safe dose of vitamin D needed to achieve high serum levels above 30 nanograms per milliliter has already been established," said Garland.

A 2011 meta-analysis by Garland and colleagues estimated that a serum level of 50 ng/ml is associated with 50 percent lower risk of breast cancer. While there are some variations in absorption, those who consume 4,000 International Units (IU) per day of vitamin D from food or a supplement normally would reach a serum level of 50 ng/ml. Garland urged patients to ask their health care provider to measure their levels before substantially increasing vitamin D intake.

According to the National Institutes of Health, the current recommended daily allowance for vitamin D is 600 IU for adults and 800 IU for people over 70 years old.


'/>"/>
Contact: Yadira Galindo
ygalindo@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related biology news :

1. Clinical trial launches to see whether vitamin D helps treat multiple sclerosis
2. Vitamin D supplements may protect against viral infections during the winter
3. Vitamin D for pregnant women and babies -- how much is enough?
4. Collaborative research team identifies safe upper level for vitamin A consumption for puppies
5. Health benefits of vitamin D dependent on type taken
6. Vitamin D with calcium shown to reduce mortality in elderly
7. 15th Vitamin D Workshop begins tomorrow
8. Link between vitamin C and twins can increase seed production in crops
9. Low vitamin D levels linked to weight gain in some older women
10. Obesity plus low vitamin D may add up to a greater risk of diabetes
11. Scientists confirm existence of vitamin deserts in the ocean
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, LLC, ... for the treatment of bacterial infections, today announced ... antibacterial candidates from Pro Bono Bio Ltd (PBB) ... of multi-drug resistant forms of Gram-negative bacteria.   The ... Infectives Ltd, a PBB group company. ...
(Date:1/24/2017)... 2017 Biopharm Reports has carried out ... of nuclear magnetic resonance spectroscopy (NMR). This involved ... current practices, developments, trends and end-user plans over ... and opportunities. These areas include growth in the ... and innovation requirements, hyphenated NMR techniques, main suppliers ...
(Date:1/19/2017)... 2017 Sensory Inc ., a ... for consumer electronics, and i nnerCore ... cybersecurity solutions, today announced a global partnership that ... worldwide to bolster security of data sensitive mobile ... authentication platforms they offer, innerCore now offers its ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... ... February 22, 2017 , ... ... innovators, engineers, and scientists from around the world, is pleased to announce the ... 22 and 23, 2017. This premier, online-only conference focused on the development and ...
(Date:2/22/2017)... Feb. 22, 2017 Aethlon Medical, Inc. (Nasdaq: ... a study that validated the ability of the Aethlon ... with increased mortality in immune-suppressed sepsis patients and also ... The objective of the study was to validate ... Epstein-Barr virus (EBV) and Herpes Simplex virus 1 (HSV1) ...
(Date:2/22/2017)... and RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2017 /PRNewswire/ ... today announced its financial results for the fourth ... "Our annual 2016 financial results reflect continued growth ... exceeded $700 million," said Martine Rothblatt, Ph.D., United ... results strengthen our ability to develop and advance ...
(Date:2/21/2017)... PARK, CA (PRWEB) , ... February 21, 2017 ... ... of the VTX-1 Liquid Biopsy System , a fully automated benchtop system ... microfluidic technology. The VTX-1 is being launched at the Molecular Medicine Tri Conference ...
Breaking Biology Technology: